November 23, 2021 Sarah Camper

Shields Develops Innovative PAH Clinical Management Model

Kerry Mello-Parker, PharmD, MBA, and Kristen Ditch, PharmD, BCCCP, recently wrote an article for Pharmacy Times discussing Shields’ new clinical management model for Pulmonary Arterial Hypertension (PAH).  PAH is a rare and progressive condition, with about 500 -1000 new cases being diagnosed each year in the U.S (Learn about PAH). PAH has no known cure.

Shields has collaborated with three of its partners – UConn Health, UMass Memorial Health Care, and Baystate Health – to implement a clinical workflow for PAH care. The care team includes PAH-trained nurses, pharmacists, and in-clinic pharmacy liaisons who assist patients with onboarding and monitor the patient throughout their clinical journey. For example, as part of the comprehensive patient care they provide for these complex patients, nurses and pharmacists help ensure patients are taking their medications appropriately as well as monitor labs specific to PAH patients.

Nurse clinicians use a standardized, validated assessment tool that measures the patient quality of life (QOL).  This measurement allows the nurses to determine the severity of the patient’s progression and ensures that proper care is managed for those who report poor quality of life. Nurses and pharmacists can then work with the patient’s team of providers to adjust medications as needed to maintain quality of care.

Treatments for PAH include medications such as ambrisentan and bosentan, which are specialty medications that require Risk Evaluation and Mitigation Strategy (REMS) protocols.

Shields provides manufacturer’s data reporting, REMS clinical compliance, and REMS desktop audit support. Analysis of data from the three initial Shields PAH program sites will be shared in the future.

For more information about our clinical management model for PAH, contact us